These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16312847)

  • 1. Leuprolide (TAP-144)--a general review.
    Calabrò G; Dell'Acqua L; La Commare P; Parisi C
    J Chemother; 1989 Jul; 1(4 Suppl):1235-6. PubMed ID: 16312847
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 3. Male breast cancer during treatment with leuprolide for prostate cancer.
    Yacoub J; Richardson C; Farmer M; Lee WR; Clark PE; Hurt G; Levine EA
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):555-6; discussion 556-7. PubMed ID: 17679929
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of premenopausal breast cancer showing remarkable elevation of serum alkaline phosphatase level during treatment with LH-RH analog.
    Ito K; Komatsu A; Kanai T; Koyama H; Hama Y; Shingu K; Fujimori M; Amano J
    Breast J; 2005; 11(6):523-4. PubMed ID: 16297128
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.
    Sharma R; Sundar S
    Eur Urol; 2007 Apr; 51(4):1146. PubMed ID: 17161523
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.
    Pitts WR
    Eur Urol; 2007 Mar; 51(3):864. PubMed ID: 16860461
    [No Abstract]   [Full Text] [Related]  

  • 7. Knowing all the side effects.
    Dodd BA
    RN; 1997 Jan; 60(1):68. PubMed ID: 9016171
    [No Abstract]   [Full Text] [Related]  

  • 8. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
    Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
    Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermatitis herpetiformis associated with administration of a gonadotropin-releasing hormone analog.
    Yu SS; Connolly MK; Berger TG; McCalmont TH
    J Am Acad Dermatol; 2006 Feb; 54(2 Suppl):S58-9. PubMed ID: 16428002
    [No Abstract]   [Full Text] [Related]  

  • 10. [Endocrine treatment of neoplasms].
    Guijosa Pernús J; Baena Herrera L; Neira Rodríguez A; González Rodríguez D; Guardiola Delegido L
    Rev Clin Esp; 1968 Feb; 108(3):207-17. PubMed ID: 5740496
    [No Abstract]   [Full Text] [Related]  

  • 11. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma.
    Wiechert A; Tüting T; Bieber T; Haidl G; Wenzel J
    Br J Dermatol; 2008 Jul; 159(1):231-3. PubMed ID: 18476960
    [No Abstract]   [Full Text] [Related]  

  • 12. Disseminated maculopapular eruption caused by leuprorelin acetate.
    Sugita K; Kabashima K; Tokura Y
    Eur J Dermatol; 2008; 18(5):603-4. PubMed ID: 18779115
    [No Abstract]   [Full Text] [Related]  

  • 13. GnRH agonists and prostate cancer.
    Dreicer R
    Am Fam Physician; 1992 Aug; 46(2):374-6. PubMed ID: 1378994
    [No Abstract]   [Full Text] [Related]  

  • 14. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.
    Schulman C; Alcaraz A; Berges R; Montorsi F; Teillac P; Tombal B
    BJU Int; 2007 Jul; 100 Suppl 1():1-5. PubMed ID: 17593201
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma.
    Crayton H; Bohlmann T; Sufit R; Graziano FM
    Clin Exp Rheumatol; 1991; 9(5):525-8. PubMed ID: 1954704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of sex hormones after administration of 7.5 or 3.75 mg depot leuprolide including noncompliant patients and escape kinetics after a single-dose treatment.
    Schilling A; Teufel K
    J Chemother; 1989 Jul; 1(4 Suppl):1250-1. PubMed ID: 16312853
    [No Abstract]   [Full Text] [Related]  

  • 17. Cutaneous metastases of prostatic small cell neuroendocrine carcinoma.
    Nakamura Y; Kashiwagi K; Nakamura A; Muto M
    Eur J Dermatol; 2014; 24(5):620-2. PubMed ID: 25075810
    [No Abstract]   [Full Text] [Related]  

  • 18. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leupoprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-8.
    Koupparis AJ
    Eur Urol; 2006 Sep; 50(3):626-7. PubMed ID: 16750291
    [No Abstract]   [Full Text] [Related]  

  • 20. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.